1  essentially equipotent with one another and oxymorphone.

2 th other strong opioids, such as morphine or oxymorphone.

3 in the past years, including hydrocodone and oxymorphone.

4 ds, naltrindole (1, NTI) and 7-(spiroindanyl)oxymorphone (2, SIOM), at delta opioid receptors.

5 nsubstituted pyridomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly

6 lease formulation of the prescription opioid oxymorphone, and 92.3% were coinfected with hepatitis C

7 uding hydrocodone, oxycodone, hydromorphone, oxymorphone, and codeine.

8 robenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone (4-9).

9 s of pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized a

10 ingredients in reformulated extended-release oxymorphone can elicit TMA.

11 ization and internalization; 2) morphine and oxymorphone caused significant desensitization without e

12 n smooth muscle assays has revealed that the oxymorphone derivatives (6, 7) are delta-selective agoni

13 cophores derived from NTI and the mu agonist oxymorphone, have been synthesized and evaluated by intr

14 (TMA) following IV abuse of extended-release oxymorphone hydrochloride (Opana ER), an oral opioid for

15 ting concentrations of etorphine, methadone, oxymorphone, or beta-CNA also reduced the current induce

16 sing MAI for a mixture of morphine, codeine, oxymorphone, oxycodone, clozapine, and buspirone and the

17 nt injection of adulterated extended-release oxymorphone tablets.

18 inaphthyl (11) derivatives of naltrexone and oxymorphone were synthesized in order to investigate the

19 action of the benzylimines of oxycodones and oxymorphones with nitrostyrenes gave a series of 4'-aryl

20       Injection-drug use of extended-release oxymorphone within a network of persons who inject drugs